PMID- 35663273
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1939-4551 (Print)
IS  - 1939-4551 (Electronic)
IS  - 1939-4551 (Linking)
VI  - 15
IP  - 5
DP  - 2022 May
TI  - Severe asthma treatment patterns: A multicenter observational study in the Gulf 
      region.
PG  - 100647
LID - 10.1016/j.waojou.2022.100647 [doi]
LID - 100647
AB  - BACKGROUND: While crucial to the assessment and improvement of asthma control, 
      insights on treatment practices in patients with severe diseases across Gulf 
      nations are lacking. This observational study describes the treatment patterns of 
      adolescents and adults with severe asthma across four countries of the Gulf 
      region and evaluates current levels of asthma control; quality of life (QoL); 
      exacerbation frequency; and the application of cellular, protein, and respiratory 
      biomarkers in assessing asthma severity and inflammation. METHODS: Patients (aged 
      >12 years, body weight >/=40 kg) with clinician-diagnosed, severe asthma (guided by 
      the 2018 Global Initiative for Asthma definition) were included in this 
      cross-sectional, multicenter, observational study conducted in the four Gulf 
      countries of Kuwait, Oman, Qatar, and the United Arab Emirates. Data on 
      demographics, treatment patterns, and laboratory parameters (blood eosinophil 
      count [BEC], levels of serum immunoglobulin E [IgE], and fractional exhaled 
      nitric oxide [FeNO]) were extracted from the medical records of patients during a 
      12-month retrospective period and transcribed onto case report forms. At the 
      Enrollment visit, patients assessed their asthma control and QoL with the 
      self-administered Asthma Control Questionnaire (ACQ) and a standardized version 
      of the Asthma Quality of Life Questionnaire (AQLQ(S)), respectively. RESULTS: 
      Among the 243 patients analyzed, (mean [standard deviation (SD)] age, 48.4 [13.9] 
      years; female, 67.5%), the inhaled corticosteroid (ICS)/long-acting beta(2) agonist 
      (LABA) combination was the most prescribed asthma medication (n = 240; 98.8%). 
      Most patients were classified as "uncontrolled," (n = 173; 71.2%) and the 
      majority (n = 206; 84.8%) experienced >/=1 exacerbation(s) in the preceding 12 
      months. The mean (SD) ACQ score was 2.1 (1.2), which indicated uncontrolled 
      asthma, and the mean (SD) total AQLQ(S) score was 4.7 (1.4), suggesting "some 
      limitation" in overall QoL. BECs during the 12-month period were elevated in most 
      patients (>300 cells/muL [n = 183; 41.7%], 150-300 cells/muL [n = 138; 31.4%], 
      <150 cells/muL [n = 118; 26.9%]), suggesting an eosinophilic asthma phenotype, 
      although no standardized threshold by which to define eosinophilia has yet been 
      confirmed. This study revealed that the biomarkers BEC, serum IgE, and FeNO 
      concentrations were obtained inconsistently by the participating centers. 
      CONCLUSIONS: Despite recommended ICS/LABA therapy being prescribed to most 
      patients for their severe disease, the majority experienced uncontrolled asthma 
      and exhibited elevated BECs. These findings indicate the need for enhanced 
      treatment strategies to improve and sustain asthma control in the Gulf region.
CI  - (c) 2022 The Author(s).
FAU - Al-Ahmad, Mona
AU  - Al-Ahmad M
AD  - Microbiology Department, Faculty of Medicine, Kuwait University, Kuwait City, 
      Kuwait.
AD  - Al Rashed Allergy Centre, Shuwaikh, Kuwait City, Kuwait.
FAU - Mobayed, Hassan
AU  - Mobayed H
AD  - Hamad Medical Corporation, Doha, Qatar.
FAU - Al Busaidi, Nasser
AU  - Al Busaidi N
AD  - Royal Hospital, Muscat, Oman.
FAU - Iqbal, Mohamed Nizam
AU  - Iqbal MN
AD  - Rashid Hospital, Dubai, United Arab Emirates.
FAU - Al Mubaihsi, Saif
AU  - Al Mubaihsi S
AD  - Sultan Qaboos University Hospital, Muscat, Oman.
FAU - Khadadah, Moussa
AU  - Khadadah M
AD  - Mubarak Al Kabeer Hospital, Jabriya, Hawalli, Kuwait.
FAU - Kassem, Abeer
AU  - Kassem A
AD  - Ibrahim Bin Hamada Obaidullah Hospital, Ras Al Khaimah, United Arab Emirates.
FAU - Abuzakouk, Mohamed
AU  - Abuzakouk M
AD  - Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
FAU - Uzbeck, Mateen
AU  - Uzbeck M
AD  - Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
FAU - Al Zaabi, Ashraf
AU  - Al Zaabi A
AD  - Zayed Military Hospital, Abu Dhabi, United Arab Emirates.
FAU - Farouk, Hisham
AU  - Farouk H
AD  - AstraZeneca Gulf, Dubai, United Arab Emirates.
LA  - eng
PT  - Journal Article
DEP - 20220519
PL  - United States
TA  - World Allergy Organ J
JT  - The World Allergy Organization journal
JID - 101481283
PMC - PMC9127696
OTO - NOTNLM
OT  - Asthma control
OT  - Biomarkers
OT  - Gulf
OT  - Quality of life
OT  - Severe asthma
EDAT- 2022/06/07 06:00
MHDA- 2022/06/07 06:01
PMCR- 2022/05/19
CRDT- 2022/06/06 13:56
PHST- 2021/09/23 00:00 [received]
PHST- 2022/02/15 00:00 [revised]
PHST- 2022/03/23 00:00 [accepted]
PHST- 2022/06/06 13:56 [entrez]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/07 06:01 [medline]
PHST- 2022/05/19 00:00 [pmc-release]
AID - S1939-4551(22)00023-0 [pii]
AID - 100647 [pii]
AID - 10.1016/j.waojou.2022.100647 [doi]
PST - epublish
SO  - World Allergy Organ J. 2022 May 19;15(5):100647. doi: 
      10.1016/j.waojou.2022.100647. eCollection 2022 May.